Harpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial Results
HPN217 (BCMA) interim data update at ASH 2022; HPN328 (DLL3) exploring dosing regimens and HPN601 (EpCAM) expected to enter the clinic in 2023 Strategic realignment to focus resources on ongoing clinical programs; restructuring workforce to support …